STAINES-UPON-THAMES, United
Kingdom, March 24, 2017
/PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a
leading global specialty pharmaceutical company, announced today it
will report fiscal 2017 first quarter earnings results for the
period of Dec. 31, 2016, to
March 31, 2017, on Monday, May 8, 2017.
A conference call for investors will begin at 8:30 a.m. Eastern Time. The call can be accessed
in three ways:
- At the Mallinckrodt website:
http://www.mallinckrodt.com/investors.
- By telephone: For both listen-only participants and those who
wish to take part in the question-and-answer portion of the call,
the telephone dial-in number in the U.S. is (877) 359-9508. For
participants outside the U.S., the dial-in number is (224)
357-2393. Callers will need to provide the Conference ID of
90995647.
- Through an audio replay: A replay of the call will be available
beginning at 11:30 a.m. Eastern Time
on Monday, May 8, 2017, and ending
at 11:59 p.m. Eastern Time on Monday, May 22, 2017.
Dial-in numbers for U.S.-based participants are (855) 859-2056 or
(800) 585-8367. Participants outside the U.S. should use the replay
dial-in number of (404) 537-3406. All callers will be required to
provide the Conference ID of 90995647.
ABOUT MALLINCKRODT
Mallinckrodt is a global business that develops,
manufactures, markets and distributes specialty pharmaceutical
products and therapies. Areas of focus include autoimmune and rare
diseases in specialty areas like neurology, rheumatology,
nephrology, pulmonology and ophthalmology; immunotherapy and
neonatal respiratory critical care therapies; and analgesics and
hemostasis products. The company's core strengths include the
acquisition and management of highly regulated raw materials and
specialized chemistry, formulation and manufacturing capabilities.
The company's Specialty Brands segment includes branded medicines
and its Specialty Generics segment includes specialty generic
drugs, active pharmaceutical ingredients and external
manufacturing. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a
channel of distribution of important company information, such as
press releases, investor presentations and other financial
information. It also uses its website to expedite public access to
time-critical information regarding the company in advance of or in
lieu of distributing a press release or a filing with the U.S.
Securities and Exchange Commission disclosing the same information.
Therefore, investors should look to the Investor Relations page of
the website for important and time-critical information. Visitors
to the website can also register to receive automatic e-mail and
other notifications alerting them when new information is made
available on the Investor Relations page of the website.
CONTACTS
Investor Relations
Coleman N.
Lannum, CFA
Senior Vice President, Investor Strategy and IRO
314-654-6649
cole.lannum@mallinckrodt.com
Daniel J. Speciale,
CPADirector,
Investor Relations
314-654-3638
daniel.speciale@mallinckrodt.com
Media
Rhonda
Sciarra
Senior Communications Manager
908-238-6765
rhonda.sciarra@mallinckrodt.com
Meredith Fischer
Chief Public Affairs Officer
314-654-3318
meredith.fischer@mallinckrodt.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mallinckrodt-plc-to-report-earnings-results-for-first-quarter-of-fiscal-2017-300428620.html
SOURCE Mallinckrodt Pharmaceuticals